Applied Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Applied Therapeutics is forecast to grow earnings and revenue by 54.7% and 53.6% per annum respectively. EPS is expected to grow by 63.7% per annum. Return on equity is forecast to be -62.7% in 3 years.
Anahtar bilgiler
54.7%
Kazanç büyüme oranı
63.7%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 27.1% |
| Gelir büyüme oranı | 53.6% |
| Gelecekteki özkaynak getirisi | -62.7% |
| Analist kapsamı | Low |
| Son güncelleme | 22 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01
Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Feb 16Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?
Feb 16Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
Nov 13We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
Aug 11We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
Jun 17Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Applied Therapeutics to resume galactosemia study for AT-007
Feb 02Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling
Nov 24
Applied Therapeutics EPS misses by $0.21
Nov 12Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 129 | -37 | N/A | N/A | 4 |
| 12/31/2025 | 48 | -52 | N/A | N/A | 5 |
| 12/31/2024 | 2 | -123 | N/A | N/A | 5 |
| 6/30/2024 | 0 | -161 | -73 | -73 | N/A |
| 3/31/2024 | 0 | -194 | -67 | -67 | N/A |
| 12/31/2023 | 10 | -120 | -55 | -55 | N/A |
| 9/30/2023 | 11 | -97 | -54 | -54 | N/A |
| 6/30/2023 | 11 | -73 | -59 | -59 | N/A |
| 3/31/2023 | 11 | -70 | -61 | -61 | N/A |
| 12/31/2022 | N/A | -83 | -78 | -78 | N/A |
| 9/30/2022 | N/A | -95 | -89 | -89 | N/A |
| 6/30/2022 | N/A | -105 | -85 | -85 | N/A |
| 3/31/2022 | N/A | -105 | -93 | -93 | N/A |
| 12/31/2021 | N/A | -106 | -91 | -91 | N/A |
| 9/30/2021 | N/A | -102 | -87 | -87 | N/A |
| 6/30/2021 | N/A | -104 | -92 | -92 | N/A |
| 3/31/2021 | N/A | -106 | -82 | -82 | N/A |
| 12/31/2020 | N/A | -94 | -78 | -78 | N/A |
| 9/30/2020 | N/A | -88 | -68 | -68 | N/A |
| 6/30/2020 | N/A | -69 | -55 | -55 | N/A |
| 3/31/2020 | N/A | -49 | -48 | -48 | N/A |
| 12/31/2019 | N/A | -46 | -36 | -36 | N/A |
| 9/30/2019 | N/A | -35 | -30 | -30 | N/A |
| 6/30/2019 | N/A | -28 | -24 | -24 | N/A |
| 3/31/2019 | N/A | -23 | -17 | -17 | N/A |
| 12/31/2018 | N/A | -17 | -11 | -11 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: APLT is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: APLT is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: APLT is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: APLT's revenue (53.6% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: APLT's revenue (53.6% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: APLT is forecast to be unprofitable in 3 years.